BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25765544)

  • 1. The DEK oncoprotein and its emerging roles in gene regulation.
    Sandén C; Gullberg U
    Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
    Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
    BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
    Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
    Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
    PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the DEK oncogene in the development of squamous cell carcinoma.
    Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
    Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
    Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
    Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.
    Qin H; Malek S; Cowell JK; Ren M
    Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
    Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
    Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.
    Sandahl JD; Coenen EA; Forestier E; Harbott J; Johansson B; Kerndrup G; Adachi S; Auvrignon A; Beverloo HB; Cayuela JM; Chilton L; Fornerod M; de Haas V; Harrison CJ; Inaba H; Kaspers GJ; Liang DC; Locatelli F; Masetti R; Perot C; Raimondi SC; Reinhardt K; Tomizawa D; von Neuhoff N; Zecca M; Zwaan CM; van den Heuvel-Eibrink MM; Hasle H
    Haematologica; 2014 May; 99(5):865-72. PubMed ID: 24441146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.
    Ageberg M; Drott K; Olofsson T; Gullberg U; Lindmark A
    Genes Chromosomes Cancer; 2008 Apr; 47(4):276-87. PubMed ID: 18181180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophil chimerism in the differential diagnosis between DEK-NUP214-positive acute myeloid leukaemia relapse and chronic graft-versus-host disease.
    e Moura de Souza CL; Bub CB; Torres MA; Velloso ED; Silveira PA; Correia RP; Bacal NS; Mangueira CL; Fernandes JF; Odone Filho V; Hamerschlak N; Campregher PV
    J Clin Pathol; 2015 Nov; 68(11):950-2. PubMed ID: 26193901
    [No Abstract]   [Full Text] [Related]  

  • 12. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.
    Ommen HB; Touzart A; MacIntyre E; Kern W; Haferlach T; Haferlach C; Tobal K; Hokland P; Schnittger S
    Eur J Haematol; 2015 Nov; 95(5):436-41. PubMed ID: 25605311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DEK oncoprotein is upregulated by multiple leukemia-associated fusion genes.
    Sandén C; Nilsson HJ; Gullberg U
    Blood Cells Mol Dis; 2015 Mar; 54(3):284-5. PubMed ID: 25524609
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Campregher PV; Halley NDS; Vieira GA; Fernandes JF; Velloso EDRP; Ali S; Mughal T; Miller V; Mangueira CLP; Odone V; Hamerschlak N
    Leuk Lymphoma; 2017 Dec; 58(12):2969-2972. PubMed ID: 28509585
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Gao MG; Fu Q; Qin YZ; Chang YJ; Wang Y; Yan CH; Xu LP; Zhang XH; Huang XJ; Zhao XS
    Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):868-874. PubMed ID: 34551474
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of the chromatin binding DEK protein in hematopoiesis and acute myeloid leukemia.
    Wilcher KE; Page ERH; Privette Vinnedge LM
    Exp Hematol; 2023 Jul; 123():18-27. PubMed ID: 37172756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene.
    von Lindern M; Fornerod M; Soekarman N; van Baal S; Jaegle M; Hagemeijer A; Bootsma D; Grosveld G
    Baillieres Clin Haematol; 1992 Oct; 5(4):857-79. PubMed ID: 1308167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.
    Piredda ML; Catalano G; Ciardi C; Divona M; Cicconi L; Panetta P; Curzi P; Garza E; Martínez-Losada C; Postorino M; Lo-Coco F; Noguera NI
    Ann Hematol; 2017 Jan; 96(1):155-157. PubMed ID: 27734129
    [No Abstract]   [Full Text] [Related]  

  • 19. YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter.
    Sitwala KV; Adams K; Markovitz DM
    Oncogene; 2002 Dec; 21(57):8862-70. PubMed ID: 12483538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
    Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
    Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.